nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—TEK—epilepsy syndrome	0.126	0.29	CbGaD
Ponatinib—RET—epilepsy syndrome	0.118	0.27	CbGaD
Ponatinib—SRC—epilepsy syndrome	0.0657	0.151	CbGaD
Ponatinib—KDR—epilepsy syndrome	0.0617	0.142	CbGaD
Ponatinib—ABCG2—epilepsy syndrome	0.0323	0.074	CbGaD
Ponatinib—ABCB11—Phenobarbital—epilepsy syndrome	0.028	0.0984	CbGbCtD
Ponatinib—CYP2D6—epilepsy syndrome	0.0188	0.0431	CbGaD
Ponatinib—CYP3A5—Oxcarbazepine—epilepsy syndrome	0.0147	0.0516	CbGbCtD
Ponatinib—ABCB1—epilepsy syndrome	0.0134	0.0308	CbGaD
Ponatinib—CYP2C8—Trimethadione—epilepsy syndrome	0.0131	0.0462	CbGbCtD
Ponatinib—CYP2C8—Fosphenytoin—epilepsy syndrome	0.0124	0.0434	CbGbCtD
Ponatinib—ABCB1—Levetiracetam—epilepsy syndrome	0.0105	0.0367	CbGbCtD
Ponatinib—CYP3A5—Carbamazepine—epilepsy syndrome	0.00923	0.0324	CbGbCtD
Ponatinib—CYP2C8—Carbamazepine—epilepsy syndrome	0.00888	0.0312	CbGbCtD
Ponatinib—CYP2C8—Primidone—epilepsy syndrome	0.00829	0.0291	CbGbCtD
Ponatinib—CYP3A5—Phenytoin—epilepsy syndrome	0.00828	0.0291	CbGbCtD
Ponatinib—CYP2C8—Phenytoin—epilepsy syndrome	0.00796	0.028	CbGbCtD
Ponatinib—CYP2C8—Propofol—epilepsy syndrome	0.00743	0.0261	CbGbCtD
Ponatinib—CYP3A5—Phenobarbital—epilepsy syndrome	0.00738	0.0259	CbGbCtD
Ponatinib—CYP3A5—Midazolam—epilepsy syndrome	0.00728	0.0256	CbGbCtD
Ponatinib—ABCB1—Clobazam—epilepsy syndrome	0.00725	0.0255	CbGbCtD
Ponatinib—CYP2C8—Phenobarbital—epilepsy syndrome	0.0071	0.0249	CbGbCtD
Ponatinib—CYP3A5—Diazepam—epilepsy syndrome	0.007	0.0246	CbGbCtD
Ponatinib—ABCB1—Lamotrigine—epilepsy syndrome	0.00698	0.0245	CbGbCtD
Ponatinib—CYP2C8—Diazepam—epilepsy syndrome	0.00673	0.0236	CbGbCtD
Ponatinib—ABCB1—Carbamazepine—epilepsy syndrome	0.00601	0.0211	CbGbCtD
Ponatinib—CYP3A4—Oxcarbazepine—epilepsy syndrome	0.00573	0.0201	CbGbCtD
Ponatinib—CYP3A5—Valproic Acid—epilepsy syndrome	0.00552	0.0194	CbGbCtD
Ponatinib—ABCB1—Phenytoin—epilepsy syndrome	0.00539	0.0189	CbGbCtD
Ponatinib—CYP3A4—Trimethadione—epilepsy syndrome	0.00533	0.0187	CbGbCtD
Ponatinib—CYP3A4—Felbamate—epilepsy syndrome	0.00533	0.0187	CbGbCtD
Ponatinib—CYP2C8—Valproic Acid—epilepsy syndrome	0.0053	0.0186	CbGbCtD
Ponatinib—CYP3A4—Fosphenytoin—epilepsy syndrome	0.00501	0.0176	CbGbCtD
Ponatinib—ABCB1—Phenobarbital—epilepsy syndrome	0.0048	0.0169	CbGbCtD
Ponatinib—ABCB1—Midazolam—epilepsy syndrome	0.00474	0.0166	CbGbCtD
Ponatinib—CYP2D6—Propofol—epilepsy syndrome	0.00474	0.0166	CbGbCtD
Ponatinib—ABCB1—Diazepam—epilepsy syndrome	0.00455	0.016	CbGbCtD
Ponatinib—CYP3A4—Clonazepam—epilepsy syndrome	0.00453	0.0159	CbGbCtD
Ponatinib—CYP3A4—Clobazam—epilepsy syndrome	0.00435	0.0153	CbGbCtD
Ponatinib—CYP3A4—Rufinamide—epilepsy syndrome	0.0037	0.013	CbGbCtD
Ponatinib—CYP3A4—Carbamazepine—epilepsy syndrome	0.0036	0.0126	CbGbCtD
Ponatinib—CYP3A4—Primidone—epilepsy syndrome	0.00336	0.0118	CbGbCtD
Ponatinib—FGFR3—skull—epilepsy syndrome	0.00336	0.0684	CbGeAlD
Ponatinib—CYP3A4—Phenytoin—epilepsy syndrome	0.00323	0.0113	CbGbCtD
Ponatinib—CYP3A4—Propofol—epilepsy syndrome	0.00301	0.0106	CbGbCtD
Ponatinib—CYP3A4—Acetazolamide—epilepsy syndrome	0.00288	0.0101	CbGbCtD
Ponatinib—CYP3A4—Phenobarbital—epilepsy syndrome	0.00288	0.0101	CbGbCtD
Ponatinib—CYP3A4—Midazolam—epilepsy syndrome	0.00284	0.00997	CbGbCtD
Ponatinib—CYP3A4—Diazepam—epilepsy syndrome	0.00273	0.00958	CbGbCtD
Ponatinib—CYP3A4—Zonisamide—epilepsy syndrome	0.00266	0.00935	CbGbCtD
Ponatinib—FGFR2—skull—epilepsy syndrome	0.0022	0.0448	CbGeAlD
Ponatinib—RET—autonomic nervous system—epilepsy syndrome	0.00217	0.0441	CbGeAlD
Ponatinib—CYP3A4—Valproic Acid—epilepsy syndrome	0.00215	0.00755	CbGbCtD
Ponatinib—FGFR4—hindbrain—epilepsy syndrome	0.00194	0.0395	CbGeAlD
Ponatinib—CYP3A4—Topiramate—epilepsy syndrome	0.00194	0.00682	CbGbCtD
Ponatinib—FGFR4—brainstem—epilepsy syndrome	0.00111	0.0227	CbGeAlD
Ponatinib—Nilotinib—TEK—epilepsy syndrome	0.000962	0.358	CrCbGaD
Ponatinib—FGFR2—hindbrain—epilepsy syndrome	0.000868	0.0177	CbGeAlD
Ponatinib—FGFR3—forebrain—epilepsy syndrome	0.000734	0.0149	CbGeAlD
Ponatinib—FGFR3—telencephalon—epilepsy syndrome	0.000675	0.0137	CbGeAlD
Ponatinib—BCR—forebrain—epilepsy syndrome	0.000635	0.0129	CbGeAlD
Ponatinib—FGFR4—head—epilepsy syndrome	0.000616	0.0125	CbGeAlD
Ponatinib—KIT—hindbrain—epilepsy syndrome	0.000603	0.0123	CbGeAlD
Ponatinib—BCR—telencephalon—epilepsy syndrome	0.000584	0.0119	CbGeAlD
Ponatinib—FGFR4—nervous system—epilepsy syndrome	0.000584	0.0119	CbGeAlD
Ponatinib—Nilotinib—CA4—epilepsy syndrome	0.000577	0.214	CrCbGaD
Ponatinib—FGFR4—central nervous system—epilepsy syndrome	0.000562	0.0114	CbGeAlD
Ponatinib—FGFR4—cerebellum—epilepsy syndrome	0.000549	0.0112	CbGeAlD
Ponatinib—FGFR3—medulla oblongata—epilepsy syndrome	0.00053	0.0108	CbGeAlD
Ponatinib—ABL1—hindbrain—epilepsy syndrome	0.000525	0.0107	CbGeAlD
Ponatinib—FGFR1—telencephalon—epilepsy syndrome	0.000519	0.0106	CbGeAlD
Ponatinib—FGFR2—brainstem—epilepsy syndrome	0.000498	0.0101	CbGeAlD
Ponatinib—FGFR3—midbrain—epilepsy syndrome	0.000484	0.00986	CbGeAlD
Ponatinib—FGFR2—forebrain—epilepsy syndrome	0.00048	0.00977	CbGeAlD
Ponatinib—FGFR3—spinal cord—epilepsy syndrome	0.000473	0.00962	CbGeAlD
Ponatinib—BCR—medulla oblongata—epilepsy syndrome	0.000459	0.00933	CbGeAlD
Ponatinib—FGFR4—brain—epilepsy syndrome	0.000446	0.00908	CbGeAlD
Ponatinib—FGFR2—telencephalon—epilepsy syndrome	0.000442	0.00898	CbGeAlD
Ponatinib—TEK—telencephalon—epilepsy syndrome	0.000423	0.00861	CbGeAlD
Ponatinib—LYN—head—epilepsy syndrome	0.000422	0.00859	CbGeAlD
Ponatinib—FGFR3—head—epilepsy syndrome	0.00042	0.00855	CbGeAlD
Ponatinib—BCR—midbrain—epilepsy syndrome	0.000419	0.00853	CbGeAlD
Ponatinib—PDGFRA—forebrain—epilepsy syndrome	0.000417	0.00849	CbGeAlD
Ponatinib—SRC—forebrain—epilepsy syndrome	0.000409	0.00832	CbGeAlD
Ponatinib—BCR—spinal cord—epilepsy syndrome	0.000409	0.00832	CbGeAlD
Ponatinib—FGFR1—medulla oblongata—epilepsy syndrome	0.000408	0.0083	CbGeAlD
Ponatinib—LYN—nervous system—epilepsy syndrome	0.0004	0.00815	CbGeAlD
Ponatinib—FGFR3—nervous system—epilepsy syndrome	0.000398	0.0081	CbGeAlD
Ponatinib—LYN—central nervous system—epilepsy syndrome	0.000385	0.00784	CbGeAlD
Ponatinib—PDGFRA—telencephalon—epilepsy syndrome	0.000384	0.0078	CbGeAlD
Ponatinib—FGFR3—central nervous system—epilepsy syndrome	0.000383	0.0078	CbGeAlD
Ponatinib—KDR—forebrain—epilepsy syndrome	0.000376	0.00766	CbGeAlD
Ponatinib—SRC—telencephalon—epilepsy syndrome	0.000376	0.00765	CbGeAlD
Ponatinib—FGFR3—cerebellum—epilepsy syndrome	0.000375	0.00763	CbGeAlD
Ponatinib—FGFR1—midbrain—epilepsy syndrome	0.000373	0.00759	CbGeAlD
Ponatinib—RET—medulla oblongata—epilepsy syndrome	0.000365	0.00743	CbGeAlD
Ponatinib—FGFR1—spinal cord—epilepsy syndrome	0.000364	0.0074	CbGeAlD
Ponatinib—BCR—head—epilepsy syndrome	0.000363	0.0074	CbGeAlD
Ponatinib—KIT—brainstem—epilepsy syndrome	0.000346	0.00703	CbGeAlD
Ponatinib—BCR—nervous system—epilepsy syndrome	0.000345	0.00701	CbGeAlD
Ponatinib—RET—midbrain—epilepsy syndrome	0.000334	0.00679	CbGeAlD
Ponatinib—TEK—medulla oblongata—epilepsy syndrome	0.000333	0.00677	CbGeAlD
Ponatinib—BCR—central nervous system—epilepsy syndrome	0.000332	0.00675	CbGeAlD
Ponatinib—RET—spinal cord—epilepsy syndrome	0.000326	0.00663	CbGeAlD
Ponatinib—BCR—cerebellum—epilepsy syndrome	0.000324	0.0066	CbGeAlD
Ponatinib—FLT3—cerebellum—epilepsy syndrome	0.000322	0.00655	CbGeAlD
Ponatinib—FGFR2—spinal cord—epilepsy syndrome	0.000309	0.0063	CbGeAlD
Ponatinib—KIT—telencephalon—epilepsy syndrome	0.000307	0.00624	CbGeAlD
Ponatinib—LYN—brain—epilepsy syndrome	0.000306	0.00623	CbGeAlD
Ponatinib—FGFR3—brain—epilepsy syndrome	0.000304	0.00619	CbGeAlD
Ponatinib—TEK—midbrain—epilepsy syndrome	0.000304	0.00619	CbGeAlD
Ponatinib—ABL1—brainstem—epilepsy syndrome	0.000301	0.00612	CbGeAlD
Ponatinib—TEK—spinal cord—epilepsy syndrome	0.000297	0.00604	CbGeAlD
Ponatinib—RET—head—epilepsy syndrome	0.000289	0.00589	CbGeAlD
Ponatinib—FGFR1—cerebellum—epilepsy syndrome	0.000289	0.00587	CbGeAlD
Ponatinib—FGFR2—head—epilepsy syndrome	0.000275	0.00559	CbGeAlD
Ponatinib—RET—nervous system—epilepsy syndrome	0.000274	0.00558	CbGeAlD
Ponatinib—KDR—medulla oblongata—epilepsy syndrome	0.000272	0.00553	CbGeAlD
Ponatinib—PDGFRA—spinal cord—epilepsy syndrome	0.000269	0.00547	CbGeAlD
Ponatinib—ABL1—telencephalon—epilepsy syndrome	0.000267	0.00543	CbGeAlD
Ponatinib—RET—central nervous system—epilepsy syndrome	0.000264	0.00537	CbGeAlD
Ponatinib—TEK—head—epilepsy syndrome	0.000264	0.00536	CbGeAlD
Ponatinib—SRC—spinal cord—epilepsy syndrome	0.000264	0.00536	CbGeAlD
Ponatinib—BCR—brain—epilepsy syndrome	0.000263	0.00536	CbGeAlD
Ponatinib—FGFR2—nervous system—epilepsy syndrome	0.000261	0.0053	CbGeAlD
Ponatinib—RET—cerebellum—epilepsy syndrome	0.000258	0.00525	CbGeAlD
Ponatinib—FGFR2—central nervous system—epilepsy syndrome	0.000251	0.00511	CbGeAlD
Ponatinib—TEK—nervous system—epilepsy syndrome	0.00025	0.00509	CbGeAlD
Ponatinib—KDR—midbrain—epilepsy syndrome	0.000248	0.00506	CbGeAlD
Ponatinib—Nilotinib—ABCG2—epilepsy syndrome	0.000246	0.0913	CrCbGaD
Ponatinib—FGFR2—cerebellum—epilepsy syndrome	0.000245	0.00499	CbGeAlD
Ponatinib—KDR—spinal cord—epilepsy syndrome	0.000242	0.00493	CbGeAlD
Ponatinib—KIT—medulla oblongata—epilepsy syndrome	0.000241	0.0049	CbGeAlD
Ponatinib—TEK—central nervous system—epilepsy syndrome	0.000241	0.0049	CbGeAlD
Ponatinib—PDGFRA—head—epilepsy syndrome	0.000239	0.00486	CbGeAlD
Ponatinib—TEK—cerebellum—epilepsy syndrome	0.000235	0.00479	CbGeAlD
Ponatinib—FGFR1—brain—epilepsy syndrome	0.000234	0.00477	CbGeAlD
Ponatinib—SRC—head—epilepsy syndrome	0.000234	0.00477	CbGeAlD
Ponatinib—CYP2D6—hindbrain—epilepsy syndrome	0.000227	0.00462	CbGeAlD
Ponatinib—PDGFRA—nervous system—epilepsy syndrome	0.000226	0.00461	CbGeAlD
Ponatinib—SRC—nervous system—epilepsy syndrome	0.000222	0.00452	CbGeAlD
Ponatinib—KIT—midbrain—epilepsy syndrome	0.00022	0.00448	CbGeAlD
Ponatinib—PDGFRA—central nervous system—epilepsy syndrome	0.000218	0.00444	CbGeAlD
Ponatinib—KDR—head—epilepsy syndrome	0.000215	0.00438	CbGeAlD
Ponatinib—KIT—spinal cord—epilepsy syndrome	0.000215	0.00437	CbGeAlD
Ponatinib—SRC—central nervous system—epilepsy syndrome	0.000214	0.00435	CbGeAlD
Ponatinib—PDGFRA—cerebellum—epilepsy syndrome	0.000213	0.00434	CbGeAlD
Ponatinib—ABL1—medulla oblongata—epilepsy syndrome	0.00021	0.00427	CbGeAlD
Ponatinib—RET—brain—epilepsy syndrome	0.00021	0.00427	CbGeAlD
Ponatinib—SRC—cerebellum—epilepsy syndrome	0.000209	0.00425	CbGeAlD
Ponatinib—Imatinib—ABCG2—epilepsy syndrome	0.000205	0.0762	CrCbGaD
Ponatinib—KDR—nervous system—epilepsy syndrome	0.000204	0.00416	CbGeAlD
Ponatinib—FGFR2—brain—epilepsy syndrome	0.000199	0.00405	CbGeAlD
Ponatinib—KDR—central nervous system—epilepsy syndrome	0.000197	0.004	CbGeAlD
Ponatinib—KDR—cerebellum—epilepsy syndrome	0.000192	0.00391	CbGeAlD
Ponatinib—ABL1—midbrain—epilepsy syndrome	0.000192	0.0039	CbGeAlD
Ponatinib—TEK—brain—epilepsy syndrome	0.000191	0.00389	CbGeAlD
Ponatinib—KIT—head—epilepsy syndrome	0.000191	0.00388	CbGeAlD
Ponatinib—ABL1—spinal cord—epilepsy syndrome	0.000187	0.00381	CbGeAlD
Ponatinib—KIT—nervous system—epilepsy syndrome	0.000181	0.00368	CbGeAlD
Ponatinib—KIT—central nervous system—epilepsy syndrome	0.000174	0.00355	CbGeAlD
Ponatinib—PDGFRA—brain—epilepsy syndrome	0.000173	0.00352	CbGeAlD
Ponatinib—KIT—cerebellum—epilepsy syndrome	0.00017	0.00347	CbGeAlD
Ponatinib—SRC—brain—epilepsy syndrome	0.00017	0.00345	CbGeAlD
Ponatinib—ABCG2—telencephalon—epilepsy syndrome	0.000168	0.00342	CbGeAlD
Ponatinib—ABL1—head—epilepsy syndrome	0.000166	0.00338	CbGeAlD
Ponatinib—Imatinib—CYP2C19—epilepsy syndrome	0.000161	0.0599	CrCbGaD
Ponatinib—ABL1—nervous system—epilepsy syndrome	0.000158	0.00321	CbGeAlD
Ponatinib—KDR—brain—epilepsy syndrome	0.000156	0.00318	CbGeAlD
Ponatinib—ABL1—central nervous system—epilepsy syndrome	0.000152	0.00309	CbGeAlD
Ponatinib—ABL1—cerebellum—epilepsy syndrome	0.000148	0.00302	CbGeAlD
Ponatinib—Nilotinib—CYP2D6—epilepsy syndrome	0.000143	0.0532	CrCbGaD
Ponatinib—KIT—brain—epilepsy syndrome	0.000138	0.00282	CbGeAlD
Ponatinib—ABCG2—medulla oblongata—epilepsy syndrome	0.000132	0.00269	CbGeAlD
Ponatinib—CYP2D6—brainstem—epilepsy syndrome	0.00013	0.00265	CbGeAlD
Ponatinib—CYP2D6—forebrain—epilepsy syndrome	0.000125	0.00255	CbGeAlD
Ponatinib—ABCG2—midbrain—epilepsy syndrome	0.000121	0.00246	CbGeAlD
Ponatinib—ABL1—brain—epilepsy syndrome	0.00012	0.00245	CbGeAlD
Ponatinib—Imatinib—CYP2D6—epilepsy syndrome	0.000119	0.0444	CrCbGaD
Ponatinib—ABCG2—spinal cord—epilepsy syndrome	0.000118	0.0024	CbGeAlD
Ponatinib—CYP2D6—telencephalon—epilepsy syndrome	0.000115	0.00235	CbGeAlD
Ponatinib—Nilotinib—ABCB1—epilepsy syndrome	0.000102	0.038	CrCbGaD
Ponatinib—ABCG2—cerebellum—epilepsy syndrome	9.35e-05	0.0019	CbGeAlD
Ponatinib—ABCB1—forebrain—epilepsy syndrome	9.03e-05	0.00184	CbGeAlD
Ponatinib—Imatinib—ALB—epilepsy syndrome	8.93e-05	0.0332	CrCbGaD
Ponatinib—Imatinib—ABCB1—epilepsy syndrome	8.52e-05	0.0317	CrCbGaD
Ponatinib—ABCB1—telencephalon—epilepsy syndrome	8.3e-05	0.00169	CbGeAlD
Ponatinib—CYP2C8—brain—epilepsy syndrome	7.81e-05	0.00159	CbGeAlD
Ponatinib—ABCG2—brain—epilepsy syndrome	7.6e-05	0.00155	CbGeAlD
Ponatinib—CYP2D6—head—epilepsy syndrome	7.19e-05	0.00146	CbGeAlD
Ponatinib—CYP3A4—nervous system—epilepsy syndrome	6.92e-05	0.00141	CbGeAlD
Ponatinib—CYP2D6—nervous system—epilepsy syndrome	6.81e-05	0.00139	CbGeAlD
Ponatinib—CYP3A4—central nervous system—epilepsy syndrome	6.67e-05	0.00136	CbGeAlD
Ponatinib—CYP2D6—central nervous system—epilepsy syndrome	6.56e-05	0.00133	CbGeAlD
Ponatinib—ABCB1—medulla oblongata—epilepsy syndrome	6.52e-05	0.00133	CbGeAlD
Ponatinib—CYP2D6—cerebellum—epilepsy syndrome	6.41e-05	0.0013	CbGeAlD
Ponatinib—ABCB1—midbrain—epilepsy syndrome	5.96e-05	0.00121	CbGeAlD
Ponatinib—ABCB1—spinal cord—epilepsy syndrome	5.82e-05	0.00118	CbGeAlD
Ponatinib—CYP2D6—brain—epilepsy syndrome	5.21e-05	0.00106	CbGeAlD
Ponatinib—ABCB1—head—epilepsy syndrome	5.17e-05	0.00105	CbGeAlD
Ponatinib—ABCB1—nervous system—epilepsy syndrome	4.9e-05	0.000997	CbGeAlD
Ponatinib—ABCB1—central nervous system—epilepsy syndrome	4.72e-05	0.00096	CbGeAlD
Ponatinib—ABCB1—cerebellum—epilepsy syndrome	4.61e-05	0.000938	CbGeAlD
Ponatinib—Body temperature increased—Carbamazepine—epilepsy syndrome	4.34e-05	0.00036	CcSEcCtD
Ponatinib—Diarrhoea—Diazepam—epilepsy syndrome	4.34e-05	0.00036	CcSEcCtD
Ponatinib—Gastrointestinal pain—Lamotrigine—epilepsy syndrome	4.34e-05	0.00036	CcSEcCtD
Ponatinib—Rash—Levetiracetam—epilepsy syndrome	4.32e-05	0.000358	CcSEcCtD
Ponatinib—Anaemia—Pregabalin—epilepsy syndrome	4.32e-05	0.000358	CcSEcCtD
Ponatinib—Dermatitis—Levetiracetam—epilepsy syndrome	4.31e-05	0.000358	CcSEcCtD
Ponatinib—Asthenia—Zonisamide—epilepsy syndrome	4.31e-05	0.000357	CcSEcCtD
Ponatinib—Mental disorder—Gabapentin—epilepsy syndrome	4.31e-05	0.000357	CcSEcCtD
Ponatinib—Dry mouth—Valproic Acid—epilepsy syndrome	4.3e-05	0.000357	CcSEcCtD
Ponatinib—Headache—Levetiracetam—epilepsy syndrome	4.29e-05	0.000356	CcSEcCtD
Ponatinib—Erythema—Gabapentin—epilepsy syndrome	4.28e-05	0.000355	CcSEcCtD
Ponatinib—Malnutrition—Gabapentin—epilepsy syndrome	4.28e-05	0.000355	CcSEcCtD
Ponatinib—Dizziness—Vigabatrin—epilepsy syndrome	4.26e-05	0.000353	CcSEcCtD
Ponatinib—Pruritus—Zonisamide—epilepsy syndrome	4.25e-05	0.000352	CcSEcCtD
Ponatinib—Oedema—Valproic Acid—epilepsy syndrome	4.22e-05	0.00035	CcSEcCtD
Ponatinib—Nausea—Propofol—epilepsy syndrome	4.21e-05	0.000349	CcSEcCtD
Ponatinib—Vomiting—Fosphenytoin—epilepsy syndrome	4.2e-05	0.000348	CcSEcCtD
Ponatinib—Diarrhoea—Felbamate—epilepsy syndrome	4.2e-05	0.000348	CcSEcCtD
Ponatinib—Body temperature increased—Lamotrigine—epilepsy syndrome	4.2e-05	0.000348	CcSEcCtD
Ponatinib—Abdominal pain—Lamotrigine—epilepsy syndrome	4.2e-05	0.000348	CcSEcCtD
Ponatinib—Dizziness—Diazepam—epilepsy syndrome	4.19e-05	0.000348	CcSEcCtD
Ponatinib—Infection—Valproic Acid—epilepsy syndrome	4.19e-05	0.000347	CcSEcCtD
Ponatinib—Leukopenia—Pregabalin—epilepsy syndrome	4.18e-05	0.000347	CcSEcCtD
Ponatinib—Rash—Fosphenytoin—epilepsy syndrome	4.17e-05	0.000346	CcSEcCtD
Ponatinib—Dermatitis—Fosphenytoin—epilepsy syndrome	4.16e-05	0.000345	CcSEcCtD
Ponatinib—Haemoglobin—Topiramate—epilepsy syndrome	4.16e-05	0.000345	CcSEcCtD
Ponatinib—Asthenia—Clonazepam—epilepsy syndrome	4.16e-05	0.000345	CcSEcCtD
Ponatinib—Back pain—Gabapentin—epilepsy syndrome	4.14e-05	0.000344	CcSEcCtD
Ponatinib—Headache—Fosphenytoin—epilepsy syndrome	4.14e-05	0.000343	CcSEcCtD
Ponatinib—Haemorrhage—Topiramate—epilepsy syndrome	4.14e-05	0.000343	CcSEcCtD
Ponatinib—Nervous system disorder—Valproic Acid—epilepsy syndrome	4.14e-05	0.000343	CcSEcCtD
Ponatinib—Thrombocytopenia—Valproic Acid—epilepsy syndrome	4.13e-05	0.000342	CcSEcCtD
Ponatinib—Asthenia—Phenytoin—epilepsy syndrome	4.13e-05	0.000342	CcSEcCtD
Ponatinib—Nausea—Midazolam—epilepsy syndrome	4.12e-05	0.000342	CcSEcCtD
Ponatinib—Hypoaesthesia—Topiramate—epilepsy syndrome	4.12e-05	0.000342	CcSEcCtD
Ponatinib—Muscle spasms—Gabapentin—epilepsy syndrome	4.12e-05	0.000341	CcSEcCtD
Ponatinib—Diarrhoea—Zonisamide—epilepsy syndrome	4.11e-05	0.000341	CcSEcCtD
Ponatinib—Asthenia—Oxcarbazepine—epilepsy syndrome	4.11e-05	0.00034	CcSEcCtD
Ponatinib—Pruritus—Clonazepam—epilepsy syndrome	4.1e-05	0.00034	CcSEcCtD
Ponatinib—Vomiting—Vigabatrin—epilepsy syndrome	4.1e-05	0.00034	CcSEcCtD
Ponatinib—Skin disorder—Valproic Acid—epilepsy syndrome	4.1e-05	0.00034	CcSEcCtD
Ponatinib—Oedema peripheral—Topiramate—epilepsy syndrome	4.08e-05	0.000338	CcSEcCtD
Ponatinib—Hyperhidrosis—Valproic Acid—epilepsy syndrome	4.08e-05	0.000338	CcSEcCtD
Ponatinib—Cough—Pregabalin—epilepsy syndrome	4.08e-05	0.000338	CcSEcCtD
Ponatinib—Pruritus—Phenytoin—epilepsy syndrome	4.07e-05	0.000337	CcSEcCtD
Ponatinib—Connective tissue disorder—Topiramate—epilepsy syndrome	4.07e-05	0.000337	CcSEcCtD
Ponatinib—Nausea—Levetiracetam—epilepsy syndrome	4.07e-05	0.000337	CcSEcCtD
Ponatinib—Rash—Vigabatrin—epilepsy syndrome	4.06e-05	0.000337	CcSEcCtD
Ponatinib—Dizziness—Felbamate—epilepsy syndrome	4.06e-05	0.000337	CcSEcCtD
Ponatinib—Dermatitis—Vigabatrin—epilepsy syndrome	4.06e-05	0.000336	CcSEcCtD
Ponatinib—Pruritus—Oxcarbazepine—epilepsy syndrome	4.05e-05	0.000336	CcSEcCtD
Ponatinib—Vision blurred—Gabapentin—epilepsy syndrome	4.04e-05	0.000335	CcSEcCtD
Ponatinib—Headache—Vigabatrin—epilepsy syndrome	4.04e-05	0.000335	CcSEcCtD
Ponatinib—Hypertension—Pregabalin—epilepsy syndrome	4.03e-05	0.000334	CcSEcCtD
Ponatinib—Vomiting—Diazepam—epilepsy syndrome	4.03e-05	0.000334	CcSEcCtD
Ponatinib—Rash—Diazepam—epilepsy syndrome	4e-05	0.000332	CcSEcCtD
Ponatinib—Dermatitis—Diazepam—epilepsy syndrome	4e-05	0.000331	CcSEcCtD
Ponatinib—Visual impairment—Topiramate—epilepsy syndrome	3.99e-05	0.000331	CcSEcCtD
Ponatinib—Myalgia—Pregabalin—epilepsy syndrome	3.98e-05	0.00033	CcSEcCtD
Ponatinib—Arthralgia—Pregabalin—epilepsy syndrome	3.98e-05	0.00033	CcSEcCtD
Ponatinib—Dizziness—Zonisamide—epilepsy syndrome	3.97e-05	0.000329	CcSEcCtD
Ponatinib—Headache—Diazepam—epilepsy syndrome	3.97e-05	0.000329	CcSEcCtD
Ponatinib—Diarrhoea—Clonazepam—epilepsy syndrome	3.96e-05	0.000329	CcSEcCtD
Ponatinib—Anaemia—Gabapentin—epilepsy syndrome	3.96e-05	0.000328	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Pregabalin—epilepsy syndrome	3.95e-05	0.000327	CcSEcCtD
Ponatinib—Asthenia—Carbamazepine—epilepsy syndrome	3.94e-05	0.000327	CcSEcCtD
Ponatinib—Diarrhoea—Phenytoin—epilepsy syndrome	3.94e-05	0.000326	CcSEcCtD
Ponatinib—Nausea—Fosphenytoin—epilepsy syndrome	3.93e-05	0.000326	CcSEcCtD
Ponatinib—Diarrhoea—Oxcarbazepine—epilepsy syndrome	3.92e-05	0.000325	CcSEcCtD
Ponatinib—Vomiting—Felbamate—epilepsy syndrome	3.9e-05	0.000324	CcSEcCtD
Ponatinib—Dry mouth—Pregabalin—epilepsy syndrome	3.89e-05	0.000322	CcSEcCtD
Ponatinib—Pruritus—Carbamazepine—epilepsy syndrome	3.89e-05	0.000322	CcSEcCtD
Ponatinib—Rash—Felbamate—epilepsy syndrome	3.87e-05	0.000321	CcSEcCtD
Ponatinib—Eye disorder—Topiramate—epilepsy syndrome	3.87e-05	0.000321	CcSEcCtD
Ponatinib—Dermatitis—Felbamate—epilepsy syndrome	3.87e-05	0.000321	CcSEcCtD
Ponatinib—Headache—Felbamate—epilepsy syndrome	3.85e-05	0.000319	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Valproic Acid—epilepsy syndrome	3.84e-05	0.000319	CcSEcCtD
Ponatinib—Flushing—Topiramate—epilepsy syndrome	3.84e-05	0.000319	CcSEcCtD
Ponatinib—Cardiac disorder—Topiramate—epilepsy syndrome	3.84e-05	0.000319	CcSEcCtD
Ponatinib—Leukopenia—Gabapentin—epilepsy syndrome	3.83e-05	0.000318	CcSEcCtD
Ponatinib—Dizziness—Clonazepam—epilepsy syndrome	3.83e-05	0.000318	CcSEcCtD
Ponatinib—Nausea—Vigabatrin—epilepsy syndrome	3.83e-05	0.000317	CcSEcCtD
Ponatinib—Vomiting—Zonisamide—epilepsy syndrome	3.82e-05	0.000317	CcSEcCtD
Ponatinib—Insomnia—Valproic Acid—epilepsy syndrome	3.81e-05	0.000316	CcSEcCtD
Ponatinib—Oedema—Pregabalin—epilepsy syndrome	3.81e-05	0.000316	CcSEcCtD
Ponatinib—Asthenia—Lamotrigine—epilepsy syndrome	3.81e-05	0.000316	CcSEcCtD
Ponatinib—Dizziness—Phenytoin—epilepsy syndrome	3.8e-05	0.000315	CcSEcCtD
Ponatinib—Rash—Zonisamide—epilepsy syndrome	3.79e-05	0.000314	CcSEcCtD
Ponatinib—Infection—Pregabalin—epilepsy syndrome	3.79e-05	0.000314	CcSEcCtD
Ponatinib—Paraesthesia—Valproic Acid—epilepsy syndrome	3.79e-05	0.000314	CcSEcCtD
Ponatinib—Dermatitis—Zonisamide—epilepsy syndrome	3.79e-05	0.000314	CcSEcCtD
Ponatinib—Dizziness—Oxcarbazepine—epilepsy syndrome	3.78e-05	0.000314	CcSEcCtD
Ponatinib—Nausea—Diazepam—epilepsy syndrome	3.77e-05	0.000312	CcSEcCtD
Ponatinib—Headache—Zonisamide—epilepsy syndrome	3.76e-05	0.000312	CcSEcCtD
Ponatinib—Dyspnoea—Valproic Acid—epilepsy syndrome	3.76e-05	0.000312	CcSEcCtD
Ponatinib—Diarrhoea—Carbamazepine—epilepsy syndrome	3.76e-05	0.000311	CcSEcCtD
Ponatinib—Angiopathy—Topiramate—epilepsy syndrome	3.76e-05	0.000311	CcSEcCtD
Ponatinib—Pruritus—Lamotrigine—epilepsy syndrome	3.75e-05	0.000311	CcSEcCtD
Ponatinib—ABCB1—brain—epilepsy syndrome	3.75e-05	0.000762	CbGeAlD
Ponatinib—Nervous system disorder—Pregabalin—epilepsy syndrome	3.74e-05	0.00031	CcSEcCtD
Ponatinib—Cough—Gabapentin—epilepsy syndrome	3.74e-05	0.00031	CcSEcCtD
Ponatinib—Thrombocytopenia—Pregabalin—epilepsy syndrome	3.73e-05	0.000309	CcSEcCtD
Ponatinib—Mediastinal disorder—Topiramate—epilepsy syndrome	3.73e-05	0.000309	CcSEcCtD
Ponatinib—Chills—Topiramate—epilepsy syndrome	3.71e-05	0.000308	CcSEcCtD
Ponatinib—Dyspepsia—Valproic Acid—epilepsy syndrome	3.71e-05	0.000308	CcSEcCtD
Ponatinib—Skin disorder—Pregabalin—epilepsy syndrome	3.7e-05	0.000307	CcSEcCtD
Ponatinib—Hypertension—Gabapentin—epilepsy syndrome	3.7e-05	0.000307	CcSEcCtD
Ponatinib—Hyperhidrosis—Pregabalin—epilepsy syndrome	3.69e-05	0.000306	CcSEcCtD
Ponatinib—Vomiting—Clonazepam—epilepsy syndrome	3.68e-05	0.000305	CcSEcCtD
Ponatinib—Decreased appetite—Valproic Acid—epilepsy syndrome	3.67e-05	0.000304	CcSEcCtD
Ponatinib—Alopecia—Topiramate—epilepsy syndrome	3.66e-05	0.000303	CcSEcCtD
Ponatinib—Vomiting—Phenytoin—epilepsy syndrome	3.66e-05	0.000303	CcSEcCtD
Ponatinib—Rash—Clonazepam—epilepsy syndrome	3.65e-05	0.000303	CcSEcCtD
Ponatinib—Dermatitis—Clonazepam—epilepsy syndrome	3.65e-05	0.000302	CcSEcCtD
Ponatinib—Arthralgia—Gabapentin—epilepsy syndrome	3.65e-05	0.000302	CcSEcCtD
Ponatinib—Myalgia—Gabapentin—epilepsy syndrome	3.65e-05	0.000302	CcSEcCtD
Ponatinib—Nausea—Felbamate—epilepsy syndrome	3.65e-05	0.000302	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Valproic Acid—epilepsy syndrome	3.64e-05	0.000302	CcSEcCtD
Ponatinib—Vomiting—Oxcarbazepine—epilepsy syndrome	3.64e-05	0.000302	CcSEcCtD
Ponatinib—Fatigue—Valproic Acid—epilepsy syndrome	3.64e-05	0.000301	CcSEcCtD
Ponatinib—Dizziness—Carbamazepine—epilepsy syndrome	3.63e-05	0.000301	CcSEcCtD
Ponatinib—Diarrhoea—Lamotrigine—epilepsy syndrome	3.63e-05	0.000301	CcSEcCtD
Ponatinib—Headache—Clonazepam—epilepsy syndrome	3.63e-05	0.000301	CcSEcCtD
Ponatinib—Rash—Phenytoin—epilepsy syndrome	3.63e-05	0.000301	CcSEcCtD
Ponatinib—Mental disorder—Topiramate—epilepsy syndrome	3.63e-05	0.000301	CcSEcCtD
Ponatinib—Dermatitis—Phenytoin—epilepsy syndrome	3.62e-05	0.0003	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Gabapentin—epilepsy syndrome	3.62e-05	0.0003	CcSEcCtD
Ponatinib—Rash—Oxcarbazepine—epilepsy syndrome	3.61e-05	0.000299	CcSEcCtD
Ponatinib—Pain—Valproic Acid—epilepsy syndrome	3.61e-05	0.000299	CcSEcCtD
Ponatinib—Constipation—Valproic Acid—epilepsy syndrome	3.61e-05	0.000299	CcSEcCtD
Ponatinib—Dermatitis—Oxcarbazepine—epilepsy syndrome	3.6e-05	0.000299	CcSEcCtD
Ponatinib—Headache—Phenytoin—epilepsy syndrome	3.6e-05	0.000299	CcSEcCtD
Ponatinib—Erythema—Topiramate—epilepsy syndrome	3.6e-05	0.000299	CcSEcCtD
Ponatinib—Malnutrition—Topiramate—epilepsy syndrome	3.6e-05	0.000299	CcSEcCtD
Ponatinib—Headache—Oxcarbazepine—epilepsy syndrome	3.59e-05	0.000297	CcSEcCtD
Ponatinib—Nausea—Zonisamide—epilepsy syndrome	3.57e-05	0.000296	CcSEcCtD
Ponatinib—Dry mouth—Gabapentin—epilepsy syndrome	3.57e-05	0.000296	CcSEcCtD
Ponatinib—Dizziness—Lamotrigine—epilepsy syndrome	3.51e-05	0.000291	CcSEcCtD
Ponatinib—Oedema—Gabapentin—epilepsy syndrome	3.5e-05	0.00029	CcSEcCtD
Ponatinib—Vomiting—Carbamazepine—epilepsy syndrome	3.49e-05	0.000289	CcSEcCtD
Ponatinib—Back pain—Topiramate—epilepsy syndrome	3.49e-05	0.000289	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Pregabalin—epilepsy syndrome	3.47e-05	0.000288	CcSEcCtD
Ponatinib—Infection—Gabapentin—epilepsy syndrome	3.47e-05	0.000288	CcSEcCtD
Ponatinib—Muscle spasms—Topiramate—epilepsy syndrome	3.47e-05	0.000287	CcSEcCtD
Ponatinib—Rash—Carbamazepine—epilepsy syndrome	3.46e-05	0.000287	CcSEcCtD
Ponatinib—Dermatitis—Carbamazepine—epilepsy syndrome	3.46e-05	0.000287	CcSEcCtD
Ponatinib—Gastrointestinal pain—Valproic Acid—epilepsy syndrome	3.45e-05	0.000286	CcSEcCtD
Ponatinib—Insomnia—Pregabalin—epilepsy syndrome	3.45e-05	0.000286	CcSEcCtD
Ponatinib—Nausea—Clonazepam—epilepsy syndrome	3.44e-05	0.000285	CcSEcCtD
Ponatinib—Headache—Carbamazepine—epilepsy syndrome	3.44e-05	0.000285	CcSEcCtD
Ponatinib—Nervous system disorder—Gabapentin—epilepsy syndrome	3.43e-05	0.000284	CcSEcCtD
Ponatinib—Paraesthesia—Pregabalin—epilepsy syndrome	3.42e-05	0.000284	CcSEcCtD
Ponatinib—Thrombocytopenia—Gabapentin—epilepsy syndrome	3.42e-05	0.000284	CcSEcCtD
Ponatinib—Nausea—Phenytoin—epilepsy syndrome	3.42e-05	0.000283	CcSEcCtD
Ponatinib—Dyspnoea—Pregabalin—epilepsy syndrome	3.4e-05	0.000282	CcSEcCtD
Ponatinib—Nausea—Oxcarbazepine—epilepsy syndrome	3.4e-05	0.000282	CcSEcCtD
Ponatinib—Vision blurred—Topiramate—epilepsy syndrome	3.4e-05	0.000282	CcSEcCtD
Ponatinib—Skin disorder—Gabapentin—epilepsy syndrome	3.4e-05	0.000282	CcSEcCtD
Ponatinib—Hyperhidrosis—Gabapentin—epilepsy syndrome	3.38e-05	0.00028	CcSEcCtD
Ponatinib—Vomiting—Lamotrigine—epilepsy syndrome	3.37e-05	0.00028	CcSEcCtD
Ponatinib—Rash—Lamotrigine—epilepsy syndrome	3.35e-05	0.000277	CcSEcCtD
Ponatinib—Dermatitis—Lamotrigine—epilepsy syndrome	3.34e-05	0.000277	CcSEcCtD
Ponatinib—Body temperature increased—Valproic Acid—epilepsy syndrome	3.33e-05	0.000276	CcSEcCtD
Ponatinib—Abdominal pain—Valproic Acid—epilepsy syndrome	3.33e-05	0.000276	CcSEcCtD
Ponatinib—Anaemia—Topiramate—epilepsy syndrome	3.33e-05	0.000276	CcSEcCtD
Ponatinib—Headache—Lamotrigine—epilepsy syndrome	3.32e-05	0.000276	CcSEcCtD
Ponatinib—Decreased appetite—Pregabalin—epilepsy syndrome	3.31e-05	0.000275	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Pregabalin—epilepsy syndrome	3.29e-05	0.000273	CcSEcCtD
Ponatinib—Fatigue—Pregabalin—epilepsy syndrome	3.29e-05	0.000273	CcSEcCtD
Ponatinib—Nausea—Carbamazepine—epilepsy syndrome	3.26e-05	0.00027	CcSEcCtD
Ponatinib—Constipation—Pregabalin—epilepsy syndrome	3.26e-05	0.00027	CcSEcCtD
Ponatinib—Pain—Pregabalin—epilepsy syndrome	3.26e-05	0.00027	CcSEcCtD
Ponatinib—Leukopenia—Topiramate—epilepsy syndrome	3.23e-05	0.000267	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Gabapentin—epilepsy syndrome	3.19e-05	0.000264	CcSEcCtD
Ponatinib—Insomnia—Gabapentin—epilepsy syndrome	3.16e-05	0.000262	CcSEcCtD
Ponatinib—Nausea—Lamotrigine—epilepsy syndrome	3.15e-05	0.000261	CcSEcCtD
Ponatinib—Cough—Topiramate—epilepsy syndrome	3.14e-05	0.000261	CcSEcCtD
Ponatinib—Paraesthesia—Gabapentin—epilepsy syndrome	3.14e-05	0.00026	CcSEcCtD
Ponatinib—Gastrointestinal pain—Pregabalin—epilepsy syndrome	3.12e-05	0.000258	CcSEcCtD
Ponatinib—Dyspnoea—Gabapentin—epilepsy syndrome	3.12e-05	0.000258	CcSEcCtD
Ponatinib—Hypertension—Topiramate—epilepsy syndrome	3.11e-05	0.000258	CcSEcCtD
Ponatinib—Dyspepsia—Gabapentin—epilepsy syndrome	3.08e-05	0.000255	CcSEcCtD
Ponatinib—Arthralgia—Topiramate—epilepsy syndrome	3.07e-05	0.000254	CcSEcCtD
Ponatinib—Myalgia—Topiramate—epilepsy syndrome	3.07e-05	0.000254	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Topiramate—epilepsy syndrome	3.05e-05	0.000253	CcSEcCtD
Ponatinib—Decreased appetite—Gabapentin—epilepsy syndrome	3.04e-05	0.000252	CcSEcCtD
Ponatinib—Asthenia—Valproic Acid—epilepsy syndrome	3.03e-05	0.000251	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Gabapentin—epilepsy syndrome	3.02e-05	0.00025	CcSEcCtD
Ponatinib—Fatigue—Gabapentin—epilepsy syndrome	3.01e-05	0.00025	CcSEcCtD
Ponatinib—Abdominal pain—Pregabalin—epilepsy syndrome	3.01e-05	0.00025	CcSEcCtD
Ponatinib—Body temperature increased—Pregabalin—epilepsy syndrome	3.01e-05	0.00025	CcSEcCtD
Ponatinib—Dry mouth—Topiramate—epilepsy syndrome	3e-05	0.000249	CcSEcCtD
Ponatinib—Constipation—Gabapentin—epilepsy syndrome	2.99e-05	0.000248	CcSEcCtD
Ponatinib—Pain—Gabapentin—epilepsy syndrome	2.99e-05	0.000248	CcSEcCtD
Ponatinib—Pruritus—Valproic Acid—epilepsy syndrome	2.98e-05	0.000247	CcSEcCtD
Ponatinib—Oedema—Topiramate—epilepsy syndrome	2.94e-05	0.000244	CcSEcCtD
Ponatinib—Infection—Topiramate—epilepsy syndrome	2.92e-05	0.000242	CcSEcCtD
Ponatinib—Diarrhoea—Valproic Acid—epilepsy syndrome	2.89e-05	0.000239	CcSEcCtD
Ponatinib—Nervous system disorder—Topiramate—epilepsy syndrome	2.88e-05	0.000239	CcSEcCtD
Ponatinib—Thrombocytopenia—Topiramate—epilepsy syndrome	2.88e-05	0.000239	CcSEcCtD
Ponatinib—Gastrointestinal pain—Gabapentin—epilepsy syndrome	2.86e-05	0.000237	CcSEcCtD
Ponatinib—Skin disorder—Topiramate—epilepsy syndrome	2.86e-05	0.000237	CcSEcCtD
Ponatinib—Hyperhidrosis—Topiramate—epilepsy syndrome	2.84e-05	0.000236	CcSEcCtD
Ponatinib—Dizziness—Valproic Acid—epilepsy syndrome	2.79e-05	0.000231	CcSEcCtD
Ponatinib—Abdominal pain—Gabapentin—epilepsy syndrome	2.76e-05	0.000229	CcSEcCtD
Ponatinib—Body temperature increased—Gabapentin—epilepsy syndrome	2.76e-05	0.000229	CcSEcCtD
Ponatinib—Asthenia—Pregabalin—epilepsy syndrome	2.74e-05	0.000227	CcSEcCtD
Ponatinib—Pruritus—Pregabalin—epilepsy syndrome	2.7e-05	0.000224	CcSEcCtD
Ponatinib—Vomiting—Valproic Acid—epilepsy syndrome	2.68e-05	0.000222	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Topiramate—epilepsy syndrome	2.68e-05	0.000222	CcSEcCtD
Ponatinib—Insomnia—Topiramate—epilepsy syndrome	2.66e-05	0.000221	CcSEcCtD
Ponatinib—Rash—Valproic Acid—epilepsy syndrome	2.66e-05	0.00022	CcSEcCtD
Ponatinib—Dermatitis—Valproic Acid—epilepsy syndrome	2.66e-05	0.00022	CcSEcCtD
Ponatinib—Headache—Valproic Acid—epilepsy syndrome	2.64e-05	0.000219	CcSEcCtD
Ponatinib—Paraesthesia—Topiramate—epilepsy syndrome	2.64e-05	0.000219	CcSEcCtD
Ponatinib—Dyspnoea—Topiramate—epilepsy syndrome	2.62e-05	0.000217	CcSEcCtD
Ponatinib—Diarrhoea—Pregabalin—epilepsy syndrome	2.61e-05	0.000216	CcSEcCtD
Ponatinib—Dyspepsia—Topiramate—epilepsy syndrome	2.59e-05	0.000215	CcSEcCtD
Ponatinib—Decreased appetite—Topiramate—epilepsy syndrome	2.56e-05	0.000212	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Topiramate—epilepsy syndrome	2.54e-05	0.000211	CcSEcCtD
Ponatinib—Fatigue—Topiramate—epilepsy syndrome	2.54e-05	0.00021	CcSEcCtD
Ponatinib—Dizziness—Pregabalin—epilepsy syndrome	2.52e-05	0.000209	CcSEcCtD
Ponatinib—Constipation—Topiramate—epilepsy syndrome	2.52e-05	0.000209	CcSEcCtD
Ponatinib—Pain—Topiramate—epilepsy syndrome	2.52e-05	0.000209	CcSEcCtD
Ponatinib—Asthenia—Gabapentin—epilepsy syndrome	2.51e-05	0.000208	CcSEcCtD
Ponatinib—Nausea—Valproic Acid—epilepsy syndrome	2.51e-05	0.000208	CcSEcCtD
Ponatinib—Pruritus—Gabapentin—epilepsy syndrome	2.47e-05	0.000205	CcSEcCtD
Ponatinib—Vomiting—Pregabalin—epilepsy syndrome	2.42e-05	0.000201	CcSEcCtD
Ponatinib—Gastrointestinal pain—Topiramate—epilepsy syndrome	2.41e-05	0.000199	CcSEcCtD
Ponatinib—Rash—Pregabalin—epilepsy syndrome	2.4e-05	0.000199	CcSEcCtD
Ponatinib—Dermatitis—Pregabalin—epilepsy syndrome	2.4e-05	0.000199	CcSEcCtD
Ponatinib—Diarrhoea—Gabapentin—epilepsy syndrome	2.39e-05	0.000198	CcSEcCtD
Ponatinib—Headache—Pregabalin—epilepsy syndrome	2.39e-05	0.000198	CcSEcCtD
Ponatinib—Abdominal pain—Topiramate—epilepsy syndrome	2.33e-05	0.000193	CcSEcCtD
Ponatinib—Body temperature increased—Topiramate—epilepsy syndrome	2.33e-05	0.000193	CcSEcCtD
Ponatinib—Dizziness—Gabapentin—epilepsy syndrome	2.31e-05	0.000192	CcSEcCtD
Ponatinib—Nausea—Pregabalin—epilepsy syndrome	2.26e-05	0.000188	CcSEcCtD
Ponatinib—Vomiting—Gabapentin—epilepsy syndrome	2.22e-05	0.000184	CcSEcCtD
Ponatinib—Rash—Gabapentin—epilepsy syndrome	2.2e-05	0.000183	CcSEcCtD
Ponatinib—Dermatitis—Gabapentin—epilepsy syndrome	2.2e-05	0.000183	CcSEcCtD
Ponatinib—Headache—Gabapentin—epilepsy syndrome	2.19e-05	0.000182	CcSEcCtD
Ponatinib—Asthenia—Topiramate—epilepsy syndrome	2.11e-05	0.000175	CcSEcCtD
Ponatinib—Pruritus—Topiramate—epilepsy syndrome	2.08e-05	0.000173	CcSEcCtD
Ponatinib—Nausea—Gabapentin—epilepsy syndrome	2.08e-05	0.000172	CcSEcCtD
Ponatinib—Diarrhoea—Topiramate—epilepsy syndrome	2.01e-05	0.000167	CcSEcCtD
Ponatinib—Dizziness—Topiramate—epilepsy syndrome	1.95e-05	0.000161	CcSEcCtD
Ponatinib—Vomiting—Topiramate—epilepsy syndrome	1.87e-05	0.000155	CcSEcCtD
Ponatinib—Rash—Topiramate—epilepsy syndrome	1.85e-05	0.000154	CcSEcCtD
Ponatinib—Dermatitis—Topiramate—epilepsy syndrome	1.85e-05	0.000154	CcSEcCtD
Ponatinib—Headache—Topiramate—epilepsy syndrome	1.84e-05	0.000153	CcSEcCtD
Ponatinib—Nausea—Topiramate—epilepsy syndrome	1.75e-05	0.000145	CcSEcCtD
Ponatinib—SRC—Immune System—FOS—epilepsy syndrome	1.25e-06	1.17e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—NOS2—epilepsy syndrome	1.25e-06	1.17e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—SRC—epilepsy syndrome	1.25e-06	1.17e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—FGF2—epilepsy syndrome	1.24e-06	1.16e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—VEGFA—epilepsy syndrome	1.24e-06	1.16e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—JUN—epilepsy syndrome	1.23e-06	1.15e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CCL2—epilepsy syndrome	1.23e-06	1.15e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—JUN—epilepsy syndrome	1.23e-06	1.15e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CCL2—epilepsy syndrome	1.23e-06	1.15e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—JUN—epilepsy syndrome	1.23e-06	1.15e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—epilepsy syndrome	1.23e-06	1.15e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—APOE—epilepsy syndrome	1.23e-06	1.15e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CACNA1D—epilepsy syndrome	1.22e-06	1.15e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—SRC—epilepsy syndrome	1.22e-06	1.15e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CYP2C19—epilepsy syndrome	1.22e-06	1.14e-05	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—AKT1—epilepsy syndrome	1.22e-06	1.14e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CASP8—epilepsy syndrome	1.22e-06	1.14e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PRKCB—epilepsy syndrome	1.22e-06	1.14e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CYP11A1—epilepsy syndrome	1.21e-06	1.14e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—IL6ST—epilepsy syndrome	1.21e-06	1.14e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AVP—epilepsy syndrome	1.21e-06	1.13e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—YWHAZ—epilepsy syndrome	1.21e-06	1.13e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—SLC2A1—epilepsy syndrome	1.21e-06	1.13e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MMP9—epilepsy syndrome	1.2e-06	1.12e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—FGF2—epilepsy syndrome	1.2e-06	1.12e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NGF—epilepsy syndrome	1.2e-06	1.12e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PLCB1—epilepsy syndrome	1.19e-06	1.12e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—TH—epilepsy syndrome	1.19e-06	1.11e-05	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—AKT1—epilepsy syndrome	1.18e-06	1.11e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—BCL2—epilepsy syndrome	1.18e-06	1.11e-05	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—AKT1—epilepsy syndrome	1.18e-06	1.1e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—FGF2—epilepsy syndrome	1.17e-06	1.1e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—epilepsy syndrome	1.17e-06	1.1e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCR5—epilepsy syndrome	1.16e-06	1.09e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CYP2D6—epilepsy syndrome	1.16e-06	1.09e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—SRC—epilepsy syndrome	1.16e-06	1.09e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—SRC—epilepsy syndrome	1.16e-06	1.08e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—RELA—epilepsy syndrome	1.15e-06	1.08e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—FGF2—epilepsy syndrome	1.15e-06	1.07e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—HMOX1—epilepsy syndrome	1.15e-06	1.07e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HES1—epilepsy syndrome	1.15e-06	1.07e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TXNRD1—epilepsy syndrome	1.14e-06	1.07e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HTR2A—epilepsy syndrome	1.14e-06	1.07e-05	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—AKT1—epilepsy syndrome	1.13e-06	1.06e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—MTOR—epilepsy syndrome	1.13e-06	1.06e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CAT—epilepsy syndrome	1.13e-06	1.06e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—AKT1—epilepsy syndrome	1.13e-06	1.05e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—FGF2—epilepsy syndrome	1.11e-06	1.04e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FYN—epilepsy syndrome	1.11e-06	1.04e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—FGF2—epilepsy syndrome	1.11e-06	1.04e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AQP1—epilepsy syndrome	1.11e-06	1.04e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—RELA—epilepsy syndrome	1.11e-06	1.04e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—H2AFX—epilepsy syndrome	1.11e-06	1.04e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—POMC—epilepsy syndrome	1.11e-06	1.04e-05	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—ALB—epilepsy syndrome	1.11e-06	1.04e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MEF2C—epilepsy syndrome	1.11e-06	1.04e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—SRC—epilepsy syndrome	1.11e-06	1.04e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ADRA2A—epilepsy syndrome	1.11e-06	1.04e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—SRC—epilepsy syndrome	1.11e-06	1.03e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—BCHE—epilepsy syndrome	1.1e-06	1.03e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—SRC—epilepsy syndrome	1.1e-06	1.03e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—FGF2—epilepsy syndrome	1.1e-06	1.03e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ABCB1—epilepsy syndrome	1.1e-06	1.03e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—RELA—epilepsy syndrome	1.09e-06	1.02e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MTOR—epilepsy syndrome	1.09e-06	1.02e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCL2—epilepsy syndrome	1.09e-06	1.02e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TSC2—epilepsy syndrome	1.08e-06	1.01e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AGT—epilepsy syndrome	1.08e-06	1.01e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—VEGFA—epilepsy syndrome	1.08e-06	1.01e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—AKT1—epilepsy syndrome	1.07e-06	1.01e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—YWHAZ—epilepsy syndrome	1.07e-06	1e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MTOR—epilepsy syndrome	1.07e-06	1e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—AKT1—epilepsy syndrome	1.07e-06	9.98e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NGF—epilepsy syndrome	1.06e-06	9.91e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—APOE—epilepsy syndrome	1.06e-06	9.91e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—POMC—epilepsy syndrome	1.05e-06	9.86e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—SLC2A1—epilepsy syndrome	1.05e-06	9.84e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—BCL2—epilepsy syndrome	1.05e-06	9.78e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—MTOR—epilepsy syndrome	1.04e-06	9.78e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—IL1B—epilepsy syndrome	1.04e-06	9.77e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ADRA2A—epilepsy syndrome	1.04e-06	9.76e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PLCB1—epilepsy syndrome	1.04e-06	9.73e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—BCHE—epilepsy syndrome	1.04e-06	9.72e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KDR—epilepsy syndrome	1.04e-06	9.71e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—TH—epilepsy syndrome	1.04e-06	9.7e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—PTGS2—epilepsy syndrome	1.04e-06	9.69e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—RELA—epilepsy syndrome	1.03e-06	9.69e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—RELA—epilepsy syndrome	1.03e-06	9.66e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCR5—epilepsy syndrome	1.03e-06	9.64e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—GPX1—epilepsy syndrome	1.02e-06	9.57e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—RELA—epilepsy syndrome	1.02e-06	9.57e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—FGF2—epilepsy syndrome	1.02e-06	9.51e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MTOR—epilepsy syndrome	1.01e-06	9.5e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MTOR—epilepsy syndrome	1.01e-06	9.48e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—JUN—epilepsy syndrome	1.01e-06	9.47e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HTR2A—epilepsy syndrome	1.01e-06	9.43e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—KCNJ11—epilepsy syndrome	1e-06	9.41e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CHRM3—epilepsy syndrome	1e-06	9.41e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—MTOR—epilepsy syndrome	1e-06	9.38e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CASP3—epilepsy syndrome	1e-06	9.37e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PRKCB—epilepsy syndrome	9.98e-07	9.34e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—IL6ST—epilepsy syndrome	9.94e-07	9.3e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—HMOX1—epilepsy syndrome	9.92e-07	9.29e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—SLC2A1—epilepsy syndrome	9.9e-07	9.27e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CASP3—epilepsy syndrome	9.83e-07	9.21e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—FGF2—epilepsy syndrome	9.81e-07	9.18e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PLCB1—epilepsy syndrome	9.8e-07	9.17e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CAT—epilepsy syndrome	9.79e-07	9.17e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—TH—epilepsy syndrome	9.76e-07	9.14e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—JUN—epilepsy syndrome	9.73e-07	9.11e-06	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—AKT1—epilepsy syndrome	9.7e-07	9.08e-06	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—AKT1—epilepsy syndrome	9.68e-07	9.06e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—ALB—epilepsy syndrome	9.6e-07	8.99e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TSC2—epilepsy syndrome	9.57e-07	8.96e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AGT—epilepsy syndrome	9.56e-07	8.95e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—JUN—epilepsy syndrome	9.55e-07	8.94e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ABCB1—epilepsy syndrome	9.53e-07	8.92e-06	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—AKT1—epilepsy syndrome	9.52e-07	8.91e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MMP9—epilepsy syndrome	9.46e-07	8.86e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—APOE—epilepsy syndrome	9.37e-07	8.77e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CASP3—epilepsy syndrome	9.33e-07	8.74e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CASP3—epilepsy syndrome	9.31e-07	8.72e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MMP9—epilepsy syndrome	9.29e-07	8.7e-06	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—AKT1—epilepsy syndrome	9.29e-07	8.7e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—MTOR—epilepsy syndrome	9.25e-07	8.66e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—IL1B—epilepsy syndrome	9.24e-07	8.65e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KDR—epilepsy syndrome	9.18e-07	8.59e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—PTGS2—epilepsy syndrome	9.17e-07	8.58e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—RELA—epilepsy syndrome	9.1e-07	8.52e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—POMC—epilepsy syndrome	9.09e-07	8.51e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—SRC—epilepsy syndrome	9.07e-07	8.49e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—JUN—epilepsy syndrome	9.07e-07	8.49e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—JUN—epilepsy syndrome	9.04e-07	8.47e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AGT—epilepsy syndrome	8.96e-07	8.39e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—JUN—epilepsy syndrome	8.95e-07	8.38e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MTOR—epilepsy syndrome	8.93e-07	8.36e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCL2—epilepsy syndrome	8.89e-07	8.33e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—GPX1—epilepsy syndrome	8.86e-07	8.29e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PRKCB—epilepsy syndrome	8.83e-07	8.27e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MMP9—epilepsy syndrome	8.82e-07	8.26e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—IL6ST—epilepsy syndrome	8.8e-07	8.24e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MMP9—epilepsy syndrome	8.8e-07	8.24e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—APOE—epilepsy syndrome	8.78e-07	8.22e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—SRC—epilepsy syndrome	8.72e-07	8.17e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—HMOX1—epilepsy syndrome	8.65e-07	8.09e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—SRC—epilepsy syndrome	8.57e-07	8.02e-06	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—AKT1—epilepsy syndrome	8.57e-07	8.02e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CAT—epilepsy syndrome	8.53e-07	7.99e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—VEGFA—epilepsy syndrome	8.5e-07	7.96e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTGS2—epilepsy syndrome	8.4e-07	7.86e-06	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—AKT1—epilepsy syndrome	8.39e-07	7.85e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—SRC—epilepsy syndrome	8.37e-07	7.84e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—VEGFA—epilepsy syndrome	8.35e-07	7.81e-06	CbGpPWpGaD
Ponatinib—KIT—Immune System—AKT1—epilepsy syndrome	8.24e-07	7.71e-06	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—AKT1—epilepsy syndrome	8.23e-07	7.7e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CASP3—epilepsy syndrome	8.21e-07	7.69e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ABCG2—epilepsy syndrome	8.19e-07	7.67e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—HMOX1—epilepsy syndrome	8.15e-07	7.63e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—SRC—epilepsy syndrome	8.13e-07	7.61e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—SRC—epilepsy syndrome	8.11e-07	7.59e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—POMC—epilepsy syndrome	8.05e-07	7.53e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CAT—epilepsy syndrome	8.04e-07	7.53e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—FGF2—epilepsy syndrome	8.04e-07	7.53e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP2C19—epilepsy syndrome	7.98e-07	7.47e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—JUN—epilepsy syndrome	7.98e-07	7.47e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP11A1—epilepsy syndrome	7.93e-07	7.43e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—VEGFA—epilepsy syndrome	7.92e-07	7.41e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—VEGFA—epilepsy syndrome	7.9e-07	7.4e-06	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—AKT1—epilepsy syndrome	7.88e-07	7.38e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCL2—epilepsy syndrome	7.87e-07	7.37e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ABCB1—epilepsy syndrome	7.82e-07	7.32e-06	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—AKT1—epilepsy syndrome	7.82e-07	7.32e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—AKT1—epilepsy syndrome	7.8e-07	7.3e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AGT—epilepsy syndrome	7.76e-07	7.27e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MMP9—epilepsy syndrome	7.76e-07	7.26e-06	CbGpPWpGaD
Ponatinib—FGFR2—Disease—AKT1—epilepsy syndrome	7.74e-07	7.25e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GPX1—epilepsy syndrome	7.71e-07	7.22e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—APOE—epilepsy syndrome	7.61e-07	7.12e-06	CbGpPWpGaD
Ponatinib—KIT—Disease—AKT1—epilepsy syndrome	7.6e-07	7.12e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—POMC—epilepsy syndrome	7.55e-07	7.06e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—RELA—epilepsy syndrome	7.46e-07	6.99e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MTOR—epilepsy syndrome	7.32e-07	6.85e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GPX1—epilepsy syndrome	7.27e-07	6.81e-06	CbGpPWpGaD
Ponatinib—FGFR1—Disease—AKT1—epilepsy syndrome	7.22e-07	6.76e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—AKT1—epilepsy syndrome	7.2e-07	6.74e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP2D6—epilepsy syndrome	7.16e-07	6.7e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—SRC—epilepsy syndrome	7.15e-07	6.7e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—FGF2—epilepsy syndrome	7.12e-07	6.66e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—VEGFA—epilepsy syndrome	6.97e-07	6.52e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ALB—epilepsy syndrome	6.88e-07	6.44e-06	CbGpPWpGaD
Ponatinib—LYN—Immune System—AKT1—epilepsy syndrome	6.88e-07	6.44e-06	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AKT1—epilepsy syndrome	6.87e-07	6.43e-06	CbGpPWpGaD
Ponatinib—ABL1—Immune System—AKT1—epilepsy syndrome	6.84e-07	6.41e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ADRA2A—epilepsy syndrome	6.82e-07	6.38e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—BCHE—epilepsy syndrome	6.79e-07	6.36e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AGT—epilepsy syndrome	6.76e-07	6.33e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CASP3—epilepsy syndrome	6.73e-07	6.3e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—APOE—epilepsy syndrome	6.63e-07	6.21e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—RELA—epilepsy syndrome	6.61e-07	6.18e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—JUN—epilepsy syndrome	6.54e-07	6.12e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—POMC—epilepsy syndrome	6.54e-07	6.12e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MTOR—epilepsy syndrome	6.48e-07	6.06e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SLC2A1—epilepsy syndrome	6.48e-07	6.06e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PLCB1—epilepsy syndrome	6.41e-07	6e-06	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—AKT1—epilepsy syndrome	6.39e-07	5.98e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TH—epilepsy syndrome	6.38e-07	5.98e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AGT—epilepsy syndrome	6.37e-07	5.97e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MMP9—epilepsy syndrome	6.36e-07	5.95e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—APOE—epilepsy syndrome	6.25e-07	5.85e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTGS2—epilepsy syndrome	6.02e-07	5.63e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ALB—epilepsy syndrome	5.96e-07	5.58e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CASP3—epilepsy syndrome	5.96e-07	5.58e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—SRC—epilepsy syndrome	5.86e-07	5.49e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—JUN—epilepsy syndrome	5.79e-07	5.42e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—VEGFA—epilepsy syndrome	5.71e-07	5.35e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—POMC—epilepsy syndrome	5.69e-07	5.33e-06	CbGpPWpGaD
Ponatinib—LCK—Immune System—AKT1—epilepsy syndrome	5.64e-07	5.28e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MMP9—epilepsy syndrome	5.63e-07	5.27e-06	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AKT1—epilepsy syndrome	5.42e-07	5.08e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—POMC—epilepsy syndrome	5.37e-07	5.02e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—HMOX1—epilepsy syndrome	5.33e-07	4.99e-06	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AKT1—epilepsy syndrome	5.32e-07	4.99e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CAT—epilepsy syndrome	5.26e-07	4.92e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTGS2—epilepsy syndrome	5.21e-07	4.88e-06	CbGpPWpGaD
Ponatinib—LCK—Disease—AKT1—epilepsy syndrome	5.2e-07	4.87e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ALB—epilepsy syndrome	5.19e-07	4.86e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ABCB1—epilepsy syndrome	5.11e-07	4.79e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—VEGFA—epilepsy syndrome	5.06e-07	4.73e-06	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AKT1—epilepsy syndrome	5.05e-07	4.73e-06	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AKT1—epilepsy syndrome	5.04e-07	4.72e-06	CbGpPWpGaD
Ponatinib—SRC—Immune System—AKT1—epilepsy syndrome	4.99e-07	4.67e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ALB—epilepsy syndrome	4.89e-07	4.58e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GPX1—epilepsy syndrome	4.75e-07	4.45e-06	CbGpPWpGaD
Ponatinib—SRC—Disease—AKT1—epilepsy syndrome	4.61e-07	4.31e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTGS2—epilepsy syndrome	4.54e-07	4.25e-06	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AKT1—epilepsy syndrome	4.45e-07	4.16e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTGS2—epilepsy syndrome	4.28e-07	4.01e-06	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—AKT1—epilepsy syndrome	4.22e-07	3.95e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AGT—epilepsy syndrome	4.17e-07	3.9e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—APOE—epilepsy syndrome	4.08e-07	3.82e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AKT1—epilepsy syndrome	3.64e-07	3.41e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—POMC—epilepsy syndrome	3.51e-07	3.28e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AKT1—epilepsy syndrome	3.23e-07	3.02e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ALB—epilepsy syndrome	3.2e-07	2.99e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AKT1—epilepsy syndrome	3.02e-07	2.83e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS2—epilepsy syndrome	2.8e-07	2.62e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AKT1—epilepsy syndrome	2.62e-07	2.45e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AKT1—epilepsy syndrome	2.28e-07	2.14e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AKT1—epilepsy syndrome	2.15e-07	2.01e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AKT1—epilepsy syndrome	1.41e-07	1.32e-06	CbGpPWpGaD
